. 2017 Apr 24;8(33):54537–54547. doi: 10.18632/oncotarget.17384

Table 1. Mean and median cfDI and cfDNA concentration of recurrent and non-recurrent groups calculated from ALU and LINE1 targets, and P-values of Wilcoxon rank sum tests comparing cfDI and log₂cfDNA concentration between recurrent and non-recurrent breast cancer patients.

Group	Index	Recurrent Patients		Non-Recurrent Patients		Comparison
Group	Index	Mean ± SD	Median	Mean ± SD	Median	P-value
ALU	cfDI	0.51±0.14	0.52	0.62±0.16	0.62	7.95E-05
	cfDNA conc (ng/μl)	1.16±3.42	0.21	0.55±0.19	0.25	0.16
LINE1	cfDI	0.43±0.15	0.39	0.56±0.19	0.54	1.11E-04
	cfDNA conc (ng/μl)	1.43±4.26	0.26	0.53±0.40	0.33	0.17

Statistically significant P < 0.05 in the univariate and multivariate analysis is highlighted in bold.

conc concentration, SD standard deviation.

Table 1. Mean and median cfDI and cfDNA concentration of recurrent and non-recurrent groups calculated from ALU and LINE1 targets, and P-values of Wilcoxon rank sum tests comparing cfDI and log2cfDNA concentration between recurrent and non-recurrent breast cancer patients.